PMC:7795856 / 205-858 JSONTXT

{"project":"LitCovid-PubTator","denotations":[{"id":"19","span":{"begin":443,"end":446},"obj":"Gene"},{"id":"21","span":{"begin":450,"end":466},"obj":"Species"},{"id":"24","span":{"begin":0,"end":3},"obj":"Species"},{"id":"25","span":{"begin":385,"end":386},"obj":"Chemical"},{"id":"26","span":{"begin":402,"end":406},"obj":"Chemical"},{"id":"31","span":{"begin":9,"end":43},"obj":"Disease"},{"id":"32","span":{"begin":122,"end":130},"obj":"Disease"},{"id":"33","span":{"begin":131,"end":141},"obj":"Disease"},{"id":"34","span":{"begin":146,"end":152},"obj":"Disease"}],"attributes":[{"id":"A19","pred":"tao:has_database_id","subj":"19","obj":"Gene:134864"},{"id":"A21","pred":"tao:has_database_id","subj":"21","obj":"Tax:562"},{"id":"A24","pred":"tao:has_database_id","subj":"24","obj":"Tax:10407"},{"id":"A25","pred":"tao:has_database_id","subj":"25","obj":"MESH:D009584"},{"id":"A31","pred":"tao:has_database_id","subj":"31","obj":"MESH:D006526"},{"id":"A32","pred":"tao:has_database_id","subj":"32","obj":"MESH:C000657245"},{"id":"A33","pred":"tao:has_database_id","subj":"33","obj":"MESH:D007239"},{"id":"A34","pred":"tao:has_database_id","subj":"34","obj":"MESH:D009369"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"HBV) and hepatitis C virus (HCV) infections and used as an immune enhancer, which also offers prospects in the context of COVID-19 infections and cancer. Manufacturing of this N-terminally acetylated 28-residue peptide is demanding, and its short plasma half-life limits in vivo efficacy and requires frequent dosing. Here, we combined the PASylation technology with enzymatic in situ N-acetylation by RimJ to produce a long-acting version of Tα1 in Escherichia coli at high yield. ESI-MS analysis of the purified fusion protein indicated the expected composition without any signs of proteolysis. SEC analysis revealed a 10-fold expanded hydrodynamic v"}

{"project":"LitCovid-PD-HP","denotations":[{"id":"T3","span":{"begin":9,"end":18},"obj":"Phenotype"},{"id":"T4","span":{"begin":146,"end":152},"obj":"Phenotype"}],"attributes":[{"id":"A3","pred":"hp_id","subj":"T3","obj":"http://purl.obolibrary.org/obo/HP_0012115"},{"id":"A4","pred":"hp_id","subj":"T4","obj":"http://purl.obolibrary.org/obo/HP_0002664"}],"text":"HBV) and hepatitis C virus (HCV) infections and used as an immune enhancer, which also offers prospects in the context of COVID-19 infections and cancer. Manufacturing of this N-terminally acetylated 28-residue peptide is demanding, and its short plasma half-life limits in vivo efficacy and requires frequent dosing. Here, we combined the PASylation technology with enzymatic in situ N-acetylation by RimJ to produce a long-acting version of Tα1 in Escherichia coli at high yield. ESI-MS analysis of the purified fusion protein indicated the expected composition without any signs of proteolysis. SEC analysis revealed a 10-fold expanded hydrodynamic v"}

{"project":"LitCovid-sentences","denotations":[{"id":"T5","span":{"begin":154,"end":317},"obj":"Sentence"},{"id":"T6","span":{"begin":318,"end":481},"obj":"Sentence"},{"id":"T7","span":{"begin":482,"end":597},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"HBV) and hepatitis C virus (HCV) infections and used as an immune enhancer, which also offers prospects in the context of COVID-19 infections and cancer. Manufacturing of this N-terminally acetylated 28-residue peptide is demanding, and its short plasma half-life limits in vivo efficacy and requires frequent dosing. Here, we combined the PASylation technology with enzymatic in situ N-acetylation by RimJ to produce a long-acting version of Tα1 in Escherichia coli at high yield. ESI-MS analysis of the purified fusion protein indicated the expected composition without any signs of proteolysis. SEC analysis revealed a 10-fold expanded hydrodynamic v"}